An animal experiment was conducted to investigate the efficacy of a long-acting genetically modified IL-7 in combination with CD19-targeted CAR-T cell therapy in mice with recurrent or refractory diffuse large B-cell lymphoma (DLBCL). The gene discussed is IL7; the disease is diffuse large B-cell lymphoma.